Recent advancements toward therapeutic vaccines against Alzheimer's disease

Expert Review of Vaccines
Krystal HerlineThomas Wisniewski

Abstract

Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized by protein aggregates of amyloid β (Aβ) and tau. These proteins have normal physiological functions, but in AD, they undergo a conformational change and aggregate as toxic oligomeric and fibrillar species with a high β-sheet content. Active and passive immunotherapeutic approaches are among the most attractive methods for targeting misfolded Aβ and tau. Promising preclinical testing of various immunotherapeutic approaches has yet to translate to cognitive benefits in human clinical trials. Knowledge gained from these past failures has led to the development of second-generation Aβ-active immunotherapies, anti-Aβ monoclonal antibodies targeting a wide array of Aβ conformations, and to a number of immunotherapies targeting pathological tau. This review covers the more recent advances in vaccine development for AD from 2016 to present. Due to the complex pathophysiology of AD, greatest clinical efficacy will most likely be achieved by concurrently targeting the most toxic forms of both Aβ and tau.

References

May 1, 1995·Neurobiology of Aging·H Braak, E Braak
Jan 1, 1996·Annual Review of Neuroscience·W J Strittmatter, A D Roses
Jul 5, 2001·Proceedings of the National Academy of Sciences of the United States of America·R B DeMattosD M Holtzman
Aug 22, 2001·Lancet·A CagninR B Banati
Sep 23, 2003·Brain Research. Brain Research Reviews·Craig S AtwoodRalph N Martins
Dec 21, 2004·Nature Neuroscience·James P ClearyKaren H Ashe
May 11, 2005·Neurology·S GilmanUNKNOWN AN1792(QS-21)-201 Study Team
Jun 3, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·So-Young Park, Adriana Ferreira
Mar 17, 2006·Nature·Sylvain LesnéKaren H Ashe
Sep 21, 2006·Brain : a Journal of Neurology·Kazuki TaharaKen-ichiro Fukuchi
Jan 26, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Pascale N LacorWilliam L Klein
May 23, 2007·Proceedings of the National Academy of Sciences of the United States of America·Andreas MuhsClaude Nicolau
Aug 24, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Ayodeji A AsuniEinar M Sigurdsson
May 31, 2008·Journal of Neuroinflammation·Jing-Ji JinKen-Ichiro Fukuchi
Aug 30, 2008·The Journal of Biological Chemistry·Charles G Glabe
Feb 13, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Henrieta ScholtzovaThomas Wisniewski
Mar 14, 2009·The Journal of Biological Chemistry·Bess FrostMarc I Diamond
Dec 15, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Allal BoutajangoutEinar M Sigurdsson
Dec 17, 2010·Journal of Internal Medicine·D Morgan
Feb 24, 2011·The Journal of Biological Chemistry·David T HickmanAndreas Muhs
Apr 22, 2011·Expert Review of Vaccines·Christian BodeDennis M Klinman
Jun 24, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Christoph WiessnerMatthias Staufenbiel
Jul 26, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Reisa A SperlingRachel J Schindler
Aug 23, 2011·PloS One·James B ReineckeMichelle L Steinhilb
Oct 12, 2011·Archives of Neurology·Susanne OstrowitzkiLuca Santarelli
Mar 31, 2012·The Journal of Biological Chemistry·Najla KfouryMarc I Diamond
Jun 8, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Martin FarlowEric R Siemers

❮ Previous
Next ❯

Citations

Nov 5, 2019·Epidemiologic Reviews·Tara Gallagher, Marc Lipsitch
Feb 25, 2020·Current Alzheimer Research·Marta KowalskaJolanta Dorszewska
Jul 1, 2020·Immunological Reviews·Virgil SchijnsEd C Lavelle
Sep 19, 2019·Expert Opinion on Drug Discovery·Ramón Cacabelos
Mar 21, 2020·Frontiers in Aging Neuroscience·Pramod N NeheteHenrieta Scholtzova
Jul 17, 2019·Nature Reviews. Neurology·Thomas Wisniewski
Jul 24, 2020·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Allison Bethanne ReissMark M Stecker
Jan 31, 2021·Life Sciences·Ewen Se ThoeAdeline Yoke Yin Chia
Mar 13, 2021·Ageing Research Reviews·Milan StoiljkovicMihály Hajós
Mar 16, 2021·Frontiers in Aging Neuroscience·Allal BoutajangoutThomas Wisniewski
May 25, 2021·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Apratim JashSyed S H Rizvi
Jan 16, 2022·Drug Discovery Today·Pieter DujardinLien Van Hoecke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

Expert Review of Vaccines
Thomas Wisniewski, Eleanor Drummond
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences
Kazushi SuzukiTakeshi Iwatsubo
Acta Biochimica Et Biophysica Sinica
Weihua WangQuanhong Ma
© 2022 Meta ULC. All rights reserved